Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have received an average rating of “Moderate Buy” from the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $19.00.

A number of equities research analysts have weighed in on the company. Truist Financial set a $17.00 price objective on Fulcrum Therapeutics in a research note on Tuesday, February 24th. Leerink Partners reiterated an “outperform” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, February 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, April 21st. Finally, Wall Street Zen upgraded Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 2nd.

Institutional Investors Weigh In On Fulcrum Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FULC. Aberdeen Group plc raised its stake in shares of Fulcrum Therapeutics by 135.0% during the third quarter. Aberdeen Group plc now owns 137,961 shares of the company’s stock worth $1,269,000 after purchasing an additional 79,265 shares during the last quarter. Braidwell LP purchased a new stake in shares of Fulcrum Therapeutics during the third quarter worth approximately $2,019,000. Boothbay Fund Management LLC raised its stake in shares of Fulcrum Therapeutics by 104.2% during the third quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company’s stock worth $6,241,000 after purchasing an additional 346,136 shares during the last quarter. Suvretta Capital Management LLC raised its stake in shares of Fulcrum Therapeutics by 5.9% during the third quarter. Suvretta Capital Management LLC now owns 5,381,000 shares of the company’s stock worth $49,505,000 after purchasing an additional 298,100 shares during the last quarter. Finally, GSA Capital Partners LLP raised its stake in shares of Fulcrum Therapeutics by 256.4% during the third quarter. GSA Capital Partners LLP now owns 116,068 shares of the company’s stock worth $1,068,000 after purchasing an additional 83,505 shares during the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Trading Down 0.3%

Shares of NASDAQ FULC opened at $6.57 on Friday. Fulcrum Therapeutics has a twelve month low of $5.88 and a twelve month high of $15.74. The stock has a 50 day moving average of $7.31 and a two-hundred day moving average of $9.27. The stock has a market cap of $437.76 million, a P/E ratio of -5.71 and a beta of 3.02.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.06. As a group, research analysts predict that Fulcrum Therapeutics will post -1.16 earnings per share for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.